Boston Scientific Corp (BSX)

Sep 23, 2026

McKesson has confirmed that data theft from its August cyberattack is limited to certain third-party applications serving its Oncology & Multispecialty business, affecting patients at cancer centers and specialty practices. The company will notify affected individuals, but has found no indication that its drug distribution business or CoverMyMeds were impacted. While specific details on the number of affected individuals and practices are still emerging, the company advises caution with unexpected communications and suggests monitoring insurance statements.

Sep 23, 2026

Abbott Laboratories (ABT) trades at a premium valuation compared to its faster-growing rivals, Stryker (SYK) and Boston Scientific (BSX), despite slower operating income growth. Abbott's diversified business and confident forecast support its valuation, while its peers offer more focused growth and higher margins at lower price-to-operating-income ratios. Investors face a decision between Abbott's stability and its competitors' more aggressive growth profiles, with Abbott's second-half performance critical to validating its premium.

Sep 23, 2026

Shares of Boston Scientific Corp. (BSX) rose 2.74% on Tuesday, outperforming its competitors and the broader market. This marked the second consecutive day of gains for the stock, despite a mixed trading session for the S&P 500 Index and a decline in the Dow Jones Industrial Average.

Sep 22, 2026

Penumbra, Inc. (PEN) is a medical devices company with a market cap of $12.51 billion, showing robust revenue growth and strong profitability. Analysts are cautiously optimistic, with an average target price suggesting a 13.93% upside potential. The company's strategic focus on innovation and expanding product offerings make it an intriguing opportunity for investors looking for capital appreciation in the healthcare sector.

Sep 22, 2026

Vertex Pharmaceuticals (VRTX) is gaining renewed attention in the healthcare sector due to company-specific clinical and regulatory catalysts, particularly its focus on medicines for serious genetic diseases. The market is shifting its focus to specialty-drug durability within a defensive sector, presenting both opportunities and risks for VRTX. Investors are advised to look for concrete updates connecting this theme to Vertex's operations, as market enthusiasm needs to be backed by execution and specific evidence.

Sep 22, 2026

This article analyzes Boston Scientific (BSX) within the context of the broader healthcare stocks market, highlighting how specific clinical and regulatory catalysts have revived interest in medical technology. It emphasizes the importance of a company-specific reading, rather than treating BSX merely as a sector proxy, to understand its performance in medical devices across various specialties. The piece concludes by noting that while market enthusiasm is evident, investors should look for concrete operational updates from Boston Scientific to confirm whether the current attention is supported by execution.

Sep 19, 2026

Citigroup has downgraded Boston Scientific (NYSE:BSX) from buy to neutral and lowered its target price from $57 to $50, citing uncertainty surrounding the company's financial future. This decision follows a cyberattack last month and increasing competitive pressure in its cardiac business, particularly affecting Watchman sales and the Farapulse system. Despite a robust future pipeline including the Tivus ultrasound platform and re-entry into TAVR, analysts are concerned about the protracted recovery from the cyberattack and current market pressures.

Sep 17, 2026

Johnson & Johnson is exiting the left atrial appendage (LAA) closure market, selling the assets of its Laminar technology to Jaguar LAA, a newly formed private company. The move follows J&J's suspension of a pivotal trial for the Laminar device due to potential post-implant unwrapping and leaks. Jaguar, formed in partnership with Santé Ventures and Laminar's management, plans to continue developing the differentiated LAA closure technology.

Sep 17, 2026

Boston Scientific (BSX) has initiated a voluntary global recall of its LUX-Dx Insertable Cardiac Monitor System and associated software due to delays in atrial fibrillation Burden Alerts. The US FDA is taking enforcement interest in this action, highlighting regulatory scrutiny of the cardiac monitoring platform. This recall adds to existing regulatory risks for Boston Scientific, which also faces other device recalls and product discontinuations.

Sep 16, 2026

The US FDA has issued a warning to Bausch + Lomb, indicating a potential recall and production interruption for the company. This warning suggests that a recall would be necessary if the firm's response to the FDA's concerns is not deemed satisfactory. The article highlights the implications for Bausch + Lomb's ophthalmic supply chain and manufacturing operations.

Sep 15, 2026

Scholar Rock, a Cambridge-based biotech company backed by Harvard immunologist Timothy Springer, has received FDA approval for its first drug. This therapy is a first-of-its-kind treatment for muscle loss associated with spinal muscular atrophy (SMA). The approval marks a significant milestone for the company and its investors.

Sep 14, 2026

Apollo Global Management is reportedly in discussions to acquire Johnson & Johnson's DePuy Synthes orthopedics unit for $20 billion, nearly a year after rumors about J&J shedding the unit began. While J&J has confirmed it is exploring options to separate its orthopedics business to maximize value creation, it stated this move is not the start of a broader divestiture program. This potential sale follows J&J's recent spin-off of Kenvue Consumer Health and the sale of its Acclarent portfolio as the company focuses on pharmaceuticals and medical devices.

Sep 14, 2026

Apollo Global Management is reportedly in non-binding talks to acquire Johnson & Johnson's orthopaedics unit, DePuy Synthes, for nearly $20 billion. This potential deal comes as J&J plans to spin out DePuy Synthes to focus on high-growth markets, despite the unit generating $9.3 billion in sales last year. Analysts suggest the $20 billion valuation might be on the lower end, hinting at potential distress or risk perceived by J&J.

Sep 14, 2026

Bausch Health (TSX:BHC) shares fell 3.80% on September 11, 2026, extending a series of declines despite recent positive operational developments like international expansion and improved reimbursement access. The persistent selling pressure is attributed to market concerns over the company's balance sheet complexity, earnings durability, product concentration, execution risk, and broader healthcare sector weakness. While the diversified pharmaceutical portfolio offers long-term potential, investors remain cautious due to financial leverage and market volatility.

Sep 13, 2026

Boston Scientific (BSX) experienced a 2.3% drop in early trading following a cyberattack on August 25, 2026, which disrupted its manufacturing and shipping. The company now expects to miss its third-quarter and full-year 2026 guidance for net sales and adjusted earnings per share, despite operations having resumed. This incident exposes operational vulnerabilities and adds near-term complications, though the demand for its products like Farapulse remains strong.

Sep 12, 2026

Boston Scientific has fully restored its manufacturing, order fulfillment, and shipping operations weeks after a cyberattack disrupted its business. The company, working with cybersecurity experts, found no evidence of ongoing threat activity or compromise. Despite the restoration, the cyberattack's impact on third-quarter and full-year sales and earnings guidance is still being assessed, with more details expected on the upcoming earnings call.